ANESTAGEL™

Post-Operative Opioid-Free Pain Management

  • Multi-billion dollar post-operative pain management opportunity
  • Pre-clinical studies complete; FDA pre-IND next
  • Phase I clinical study manufacturing line underway

InSitu Biologics is currently in the investigational pre-clinical stage.
AnestaGel™ is not yet for sale in any geography.

Who We Are

InSitu Biologics is an emerging biotech company focusing on development of AnestaGel™, a long-lasting and long-acting non-opiate painkiller. The sustained release drug AnestaGel™ is expected to be used in post-operative surgical procedures. AnestaGel™ may be a solution in relieving pain for broken bones, cosmetic surgery, hip/knee replacements, hernias, and more.

Pre-Clinical Results

As compared to EXPAREL (Pacira, Inc.), the industry leading post-operative pain treatment

300% Longer

Initial animal study revealed AnestaGel™ lasted up to 300% longer

8x More Capacity

AnestaGel™ carried 8 times more payload

72+ Hours

AnestaGel™ had full nerve block beyond 72 hours

See our study at the Journal of Pain Research